|
|
 Previous Article | Table of Contents | Next Article 
Allogeneic marrow transplantation for children with juvenile chronic
myelogenous leukemia
JE Sanders, CD Buckner, ED Thomas, R Fleischer, KM Sullivan, FA Appelbaum and R Storb
Fred Hutchinson Cancer Reasearch Center, Division of Clinical Research,
Seattle, WA 98104.
Fourteen children between the ages of 2 and 5 years with juvenile chronic
myelogenous leukemia were given cyclophosphamide, total-body irradiation,
and marrow transplants. Unmodified marrow was given to six patients who
received marrow from HLA-identical siblings and eight patients who received
marrow from family members HLA identical for one haplotype but mismatched
for one to three loci on the nonshared haplotype. Five patients died of
transplant-related complications, and three relapsed at 48, 81, and 1,670
days posttransplant and died of leukemia. Six patients survive in
continuous remission from 0.5 to 11.5 years posttransplant.
Volume 71,
Issue 4,
pp. 1144-1146,
04/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Locatelli, P. Nollke, M. Zecca, E. Korthof, E. Lanino, C. Peters, A. Pession, H. Kabisch, C. Uderzo, C. S. Bonfim, et al.
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial
Blood,
January 1, 2005;
105(1):
410 - 419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Woods, D. R. Barnard, T. A. Alonzo, J. D. Buckley, N. Kobrinsky, D. C. Arthur, J. Sanders, S. Neudorf, S. Gold, and B. J. Lange
Prospective Study of 90 Children Requiring Treatment for Juvenile Myelomonocytic Leukemia or Myelodysplastic Syndrome: A Report From the Children's Cancer Group
J. Clin. Oncol.,
January 15, 2002;
20(2):
434 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Emanuel, R. C. Snyder, T. Wiley, B. Gopurala, and R. P. Castleberry
Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors
Blood,
January 15, 2000;
95(2):
639 - 645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Luna-Fineman, K. M. Shannon, S. K. Atwater, J. Davis, M. Masterson, J. Ortega, J. Sanders, P. Steinherz, V. Weinberg, and B. J. Lange
Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 Patients
Blood,
January 15, 1999;
93(2):
459 - 466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. O. Iversen and M. Sioud
Modulation of Granulocyte-Macrophage Colony-Stimulating Factor Gene Expression by a Tumor Necrosis Factor alpha Specific Ribozyme in Juvenile Myelomonocytic Leukemic Cells
Blood,
December 1, 1998;
92(11):
4263 - 4268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. O. Iversen, I. D. Lewis, S. Turczynowicz, H. Hasle, C. Niemeyer, K. Schmiegelow, S. Bastiras, A. Biondi, T. P. Hughes, and A. F. Lopez
Inhibition of Granulocyte-Macrophage Colony-Stimulating Factor Prevents Dissemination and Induces Remission of Juvenile Myelomonocytic Leukemia in Engrafted Immunodeficient Mice
Blood,
December 15, 1997;
90(12):
4910 - 4917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Arico, A. Biondi, and C.-H. Pui
Juvenile Myelomonocytic Leukemia
Blood,
July 15, 1997;
90(2):
479 - 488.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, M. Arico, J. Donadieu, R. P. Castleberry, and P. D. Emanuel
Isotretinoin for Juvenile Chronic Myelogenous Leukemia
N. Engl. J. Med.,
June 1, 1995;
332(22):
1520 - 1521.
[Full Text]
|
|
|
|
|
|
|
R. P. Castleberry, P. D. Emanuel, K. S. Zuckerman, S. Cohn, L. Strauss, R. L. Byrd, A. Homans, S. Chaffee, R. Nitschke, and R. J. Gualtieri
A Pilot Study of Isotretinoin in the Treatment of Juvenile Chronic Myelogenous Leukemia
N. Engl. J. Med.,
December 22, 1994;
331(25):
1680 - 1684.
[Abstract]
[Full Text]
|
|
|
|
|
